The addition of durvalumab to standard neoadjuvant chemotherapy significantly improved pathologic complete response over neoadjuvant chemotherapy alone in patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction cancers.
AstraZeneca PLC on Friday reported positive results from planned interim analysis of a phase three trial evaluating its Imfinzi drug in gastric and gastroesophageal junction cancers.
The. | June 2, 2023